TEVA-LOVASTATIN 20 MG
LOVASTATIN : 20 MG · DIN 02246542 · TEVA CANADA LIMITED
Health Canada status: CANCELLED POST MARKET
What is TEVA-LOVASTATIN?
TEVA-LOVASTATIN 20 MG contains LOVASTATIN : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02246542, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 19-Jun-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-LOVASTATIN used for?
Adjunct to diet for reduction of elevated total and LDL-C in primary hypercholesterolemia (Types IIa and IIb). Slows progression of coronary atherosclerosis in patients with coronary heart disease.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02246542 |
|---|---|
| Brand name | TEVA-LOVASTATIN |
| Generic / active ingredient | LOVASTATIN : 20 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 20 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C10AA02 LOVASTATIN |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 19-Jun-2018 |
How is it administered?
Initial dose 20 mg once daily with evening meal. Range 20-80 mg/day. Adjustments at intervals of 4 weeks or more. Max 20 mg/day with danazol, verapamil, diltiazem, or fibrates.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (refers to Storage and Stability section).
How is it supplied?
Not explicitly detailed in provided text (refers to Dosage Forms, Composition and Packaging section).
Contraindications
Hypersensitivity; active liver disease; unexplained persistent transaminase elevations; pregnancy and nursing; concomitant potent CYP3A4 inhibitors or cyclosporine.
Warnings and precautions
Risk of myopathy/rhabdomyolysis (dose-related). Monitor liver function at baseline and periodically. Risk of increased fasting glucose/HbA1c. Use caution in elderly and those with renal impairment.
Is LOVASTATIN in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by AA PHARMA INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C10AA02 LOVASTATIN. 2 of 35 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| LOVASTATIN | 20 MG | TABLET | AA PHARMA INC | MARKETED | DIN 02220172 |
| LOVASTATIN | 40 MG | TABLET | AA PHARMA INC | MARKETED | DIN 02220180 |
| ACT LOVASTATIN | 20 MG | TABLET | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 02248572 |
| ACT LOVASTATIN | 40 MG | TABLET | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 02248573 |
| AVA-LOVASTATIN | 20 MG | TABLET | AVANSTRA INC | CANCELLED POST MARKET | DIN 02364239 |
| AVA-LOVASTATIN | 40 MG | TABLET | AVANSTRA INC | CANCELLED POST MARKET | DIN 02364247 |
| DOM-LOVASTATIN | 20 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02247231 |
| DOM-LOVASTATIN | 40 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02247232 |
| LOVASTATIN | 20 MG | TABLET | SANIS HEALTH INC | CANCELLED POST MARKET | DIN 02353229 |
| LOVASTATIN | 20 MG | TABLET | COBALT PHARMACEUTICALS COMPANY | CANCELLED PRE MARKET | DIN 02344335 |
Who else supplies LOVASTATIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LOVASTATIN appears in 3 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.